KESTINE

This brand name is authorized in Estonia, Finland, Italy, Lithuania, Netherlands, Singapore, South Africa, Turkey.

Active ingredients

The drug KESTINE contains one active pharmaceutical ingredient (API):

1	Ebastine UNII TQD7Q784P1 - EBASTINE
	Ebastine has been shown to produce a rapid and long-lasting inhibition of histamine-induced effect and to have a strong affinity towards H1-receptors.
	Read more about Ebastine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KESTINE Coated tablet	MPI, EU: SmPC	Web Search

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R06AX22	Ebastine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use
Discover more medicines within R06AX22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1009976, 1077937, 1077948, 1081617, 1120330, 1120341, 1120352, 1137046
FI	Lääkealan turvallisuus- ja kehittämiskeskus	015084, 015095, 015515, 023058, 023420, 065140
IT	Agenzia del Farmaco	034930014, 034930141
LT	Valstybinė vaistų kontrolės tarnyba	1003913, 1011680, 1012601, 1086459, 1087824
NL	Z-Index G-Standaard, PRK	46922
SG	Health Sciences Authority	09435P, 15644P
TR	İlaç ve Tıbbi Cihaz Kurumu	8699586092121, 8699586092237
ZA	Health Products Regulatory Authority	29/5.7.1/0344